|
- 积分
- 85
- 威望
- 85
- 包包
- 41
|
1Clinical Benefit of Eplerenone in Patients With Mild Symptoms of Systolic Heart Failure Already Receiving Optimal Best Practice Background Drug Therapy: Analysis of the EMPHASIS-HF Study 7 r6 V; |" D# z- z8 K# ]
http://circheartfailure.ahajournals.org/content/6/4/711.long
8 t( D7 E" @( X2 e, v4 t2，Incidence, Determinants, and Prognostic Significance of Hyperkalemia and Worsening Renal Function in Patients With Heart Failure Receiving the Mineralocorticoid Receptor Antagonist Eplerenone or Placebo in Addition to Optimal Medical Therapy: Results From the Eplerenone in Mild Patients Hospitalization and Survival Study in Heart Failure (EMPHASIS-HF) http://circheartfailure.ahajournals.org/content/7/1/51.long2 q: w& D; q& O( L9 B# S& R: _" L& s
3，Incidence, Predictors and Outcomes Related to Hypo and Hyperkalemia in Severe Heart Failure Patients Treated with a Mineralocorticoid Receptor Antagonist.6 J6 ^. b* d, P* T5 t1 Y
http://www-ncbi-nlm-nih-gov.ezpr ... Receptor+Antagonist9 f% `" [8 K p! `& l+ P( M
|
|
发表于 2014-5-28 23:30
发表于 2014-5-29 09:31
